Suggested remit - To evaluate the benefits and costs of OTL-101 within its marketing authorisation for treating adenosine deaminase deficiency–severe combined immunodeficiency caused by for national commissioning by NHS England.
- Status:
- Awaiting development
- Decision:
- None selected
- Process:
- HST
- ID number:
- 1152
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 27 July 2018 - 24 August 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 22 August 2018 | On receiving timing information from the company that will market the technology, NICE has agreed that scoping the topic at this time would not be appropriate. Consequently the consultation on the draft scope will not continue at this time. The consultation will then be rescheduled to take place in line with such timings. We apologise for any inconvenience this may cause. |
For further information on our processes and methods, please see our CHTE processes and methods manual